Why ENDORET® Technology? | BTI Biotechnology Institute

Research underscores that the plasma obtained from whole blood features an ideal concentration of proteins and growth factors. These components actively promote tissue regeneration and improve the effectiveness of standard clinical treatments.

Why use ENDORET® technology instead of other PRPs?

AUTOLOGOUS AND SAFE
- Eliminates adverse effects and incompatibility risks [1]
- Promotes natural homeostasis
- Stimulates the proliferation and migration of cells
- Encourages the body's own secretion of proteins from the extracellular matrix
OPTIMUM PLATELET CONCENTRATION
- Achieves a platelet concentration 2 to 3 times the baseline level
- Creates a balance between growth factors derived from platelets and those derived from plasma [2] [3]
REDUCED INFLAMMATORY CONTENT
- Contains insignificant amount leukocytes or inflammatory proteins [2] [4]
- Helps reduce inflammation, pain, and tissue fibrosis [5]
- Preserves the structural integrity of the fibrin matrix over time [5] [6]
CONTROLLED ACTIVATION
- Promotes the targeted release of growth factors from platelets
- Induces the polymerization of the fibrin matrix for a stable scaffold [7]
DUAL EFFECT AND BIOAVAILABILITY
- ENDORET® Technology provides a dual-action effect on tissues [8] [9]:
  
  • Immediate action: Delivers an initial impact from growth factors upon application
  • Sustained Action: The fibrin matrix acts as a natural reservoir, providing a prolonged and gradual release of factors over time
VERSATILITY
- Allows for the preparation of specific formulations tailored to diverse tissue types and clinical requirements.
SECURITY AND COMPLIANCE GUARANTEES
- All medical equipment and devices used in the closed-system ENDORET® Technology:
  
  • Have passed extensive quality controls to comply with current regulations, including endotoxin and sterility testing
  • Are manufactured from fully biocompatible materials
  • Meet all requirements for clinical medical devices as established by relevant healthcare authorities across the globe
SCIENTIFIC EVIDENCE
- The efficacy and safety of ENDORET® Technology are supported by over 250 indexed scientific publications.
TRAINING
- A wide range of training programs is available, adapted to different medical specialties, to help professionals achieve excellence in their daily clinical practice.

VERSATILITY

ENDORET® Technology makes it possible to create different product formulations that can be adapted to a variety of clinical applications.

As a closed system, ENDORET® Technology provides all the necessary tools to obtain Plasma Rich in Growth Factors (PRGF) from a patient's own blood, enabling its precise application directly at the site of injury.

References

[1] Anitua E, Orive G, Aguirre JJ, Andía I.
Clinical outcome of immediately loaded dental implants bioactivated with plasma rich in growth factors: a 5-year retrospective study.
J Periodontol. 2008 Jul;79(7):1168-76.

[2] Anitua E, Sánchez M, Zalduendo MM, de la Fuente M, Prado R, Orive G, Andía I.
Fibroblastic response to treatment with different preparations rich in growth factors.
Cell Prolif. 2009;42:162-170.

[3] Anitua E, Sanchez M, Prado R, Orive G.
The type of platelet-rich plasma may influence the safety of the approach.
Knee Surg Sports Traumatol Arthrosc. 2014. Jul;22(7):1708-9.

[4] Nishiyama K, Okudera T, Watanabe T, Isobe K, Suzuki M, Masuki H, Okudera H, Uematsu K, Nakata K, Kawase T.
Basic characteristics of plasma rich in growth factors (PRGF): blood cell components and biological effects.
Clin Exp Dent Res. 2016 Mar 18;2(2):96-103.

[5] Anitua E, Zalduendo M, Troya M, Padilla S, Orive G.
Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties.
PLoS One. 2015 Mar 30;10(3):e0121713.

[6] Filardo G, Kon E, Pereira Ruiz MT, Vaccaro F, Guitaldi R, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M.
Platelet-rich plasma intraarticular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach.
Knee Surg Sports Traumatol Arthrosc. 2012 Oct;20(10):2082-91.

[7] Anitua E, Zalduendo MM, Alkhraisat MH, Orive G.
Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors.
Ann Anat. 2013 Oct;195(5):461-6.

[8] Anitua E, Zalduendo MM, Alkhraisat MH, Orive G.
Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors.
Ann Anat. 2013 Oct;195(5):461-6.

[9] Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, Orive G, Azofra J, Andia I.
Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities.
J Biomed Mater Res A. 2006;77:285-293.

If you are interested or you want further information

ENDORET® Technology

References

Information note